Validation of the pharmacoeconomic model of emtricitabin/ rilpivirine/ tenofovir (eviplera) inclusion in highly active antiretroviral therapy of HIV/AIDS in the Russian Federation
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.